Core Viewpoint - Kubo Medical-B (02216) shares rose nearly 10%, currently up 9.96% at HKD 2.65, with a trading volume of HKD 3.29 million [1] Group 1: Product Development and Regulatory Approvals - Kubo Medical announced that its BroncTarget lung-targeted radiofrequency ablation system has entered the special review process for innovative medical devices by the National Medical Products Administration of China, indicating recognition of its core technology originality and clinical value [1] - The confirmatory clinical trials for the BroncTarget system are currently underway, with 28 hospitals across the country actively recruiting participants [1] Group 2: Market Expansion and Product Launches - Kubo Medical's self-developed BroncAblate intelligent lung radiofrequency ablation system has received registration approval from the Hong Kong Department of Health, marking its commercial launch in Hong Kong as the world's first natural orifice radiofrequency ablation device for lung cancer intervention [1] - Concurrently, the FleXNeedleCN single-use endoscopic aspiration biopsy needle has also been registered by the Hong Kong Department of Health [1] - The BroncTru single-use bronchial dilation catheter has successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market [1]